title: Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
authors.affiliation: Duke Clinical Research Institute, Durham, NC 27715, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: D
authors.initials: D
authors.lastname: Stump
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: D B
authors.initials: DB
authors.lastname: Mark
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009656:North America; D012189:Retrospective Studies; D013300:Streptokinase / Q000191:economics* / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics*; D010959:Tissue Plasminogen Activator / Q000191:economics* / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator